NVAX:NASDAQ
Novavax Inc
$12.58
arrow_downward
-1.37%(-0.18) 1D
Oct 12, 1:30:22 PM GMT-4 · USD
search
All symbols
| Symbol | Price | Change | % Change |
|---|
insights_autoGenerating top insights for NVAX...
Open
$12.61
High
$12.96
Low
$12.19
Mkt. cap
2.07B
Avg. vol.
7.28M
Volume
5.68M
52-wk high
$13.38
52-wk low
$6.20
EPS
-$1.52
Beta
2.44
Shares outstanding
164.95M
No. of employees
749
Open
$12.61
High
$12.96
Low
$12.19
Mkt. cap
2.07B
Avg. vol.
7.28M
Volume
5.68M
52-wk high
$13.38
52-wk low
$6.20
EPS
-$1.52
Beta
2.44
Shares outstanding
164.95M
No. of employees
749
News stories
From web sources and news partners
Zacks
·
2 hours ago
Vaccine Stocks Rally on Reports of U.S.-led Push for Cancer Vaccines
Benzinga
·
8 hours ago
Stephen King Slams Trump’s New Press Secretary as Past Vaccine Conspiracy Theories, Third-Term Posts Spark Fresh Controversy: 'She Appears to Have Tried to…'
Simply Wall Street
·
1 day ago
Novavax (NVAX) Could Be 82% Overvalued On Plague Headlines And Pfizer Deal Focus
24/7 Wall St.
·
2 days ago
Novavax Soars 16%, Moderna Surges 11%, Merck Climbs 3% as Biotech Rallies
Profile
Novavax, Inc., based in Gaithersburg, Maryland, develops vaccines to counter infectious diseases. The company developed the Novavax COVID-19 vaccine, now commercialized by Sanofi. The company also develops vaccines for influenza, respiratory syncytial virus, avian flu, shingles, Clostridioides difficile, and malaria.
Novavax develops proprietary immune-stimulating saponin-based immunologic adjuvants at a wholly owned Swedish subsidiary, Novavax AB. One of these, Matrix-M, is used in the Novavax COVID-19 vaccine. Wikipedia
About Novavax Inc
CEOJohn C. Jacobs
Employees749
Founded1987
HeadquartersGaithersburg, Maryland, United States
SectorBiotechnology
Websitenovavax.com